Allergenicity and immunogenicity of the major mugwort pollen allergen Art v 1 chemically modified by acetylation

Perovic, I; Milovanović, M; Stanić, Dragana; Burazer, Lidija; Petrović, Danijela; Polović, Natalija; Gafvelin, Guro; Hage, Marianne van; Jankov, Ratko M.; Veličković, Tanja Ćirković

doi:10.1111/j.1365-2222.2008.03158.x

Cited by 9 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetylation has been reported for proteins produced or shuttled to the chloroplast (Lehtimaki et al ., ). Interestingly, acetylation of Art v 1, the major mugwort pollen allergen, reduces allergenicity in vivo and in vitro (Perovic et al ., ). Further structural characterization will be necessary to elucidate the relationship of reduced IgE binding and the structure of algal‐produced peanut allergens to determine whether this phenomenon is specific to Ara h 1 and Ara h 2 or a more general characteristic of chloroplast‐produced proteins.…”

Section: Discussionmentioning

confidence: 97%

Immunotherapy using algal‐produced Ara h 1 core domain suppresses peanut allergy in mice

Gregory

Shepley-McTaggart

Umpierrez

et al. 2016

Plant Biotechnology Journal

View full text Add to dashboard Cite

SummaryPeanut allergy is an IgE‐mediated adverse reaction to a subset of proteins found in peanuts. Immunotherapy aims to desensitize allergic patients through repeated and escalating exposures for several months to years using extracts or flours. The complex mix of proteins and variability between preparations complicates immunotherapy studies. Moreover, peanut immunotherapy is associated with frequent negative side effects and patients are often at risk of allergic reactions once immunotherapy is discontinued. Allergen‐specific approaches using recombinant proteins are an attractive alternative because they allow more precise dosing and the opportunity to engineer proteins with improved safety profiles. We tested whether Ara h 1 and Ara h 2, two major peanut allergens, could be produced using chloroplast of the unicellular eukaryotic alga, Chlamydomonas reinhardtii. C. reinhardtii is novel host for producing allergens that is genetically tractable, inexpensive and easy to grow, and is able to produce more complex proteins than bacterial hosts. Compared to the native proteins, algal‐produced Ara h 1 core domain and Ara h 2 have a reduced affinity for IgE from peanut‐allergic patients. We further found that immunotherapy using algal‐produced Ara h 1 core domain confers protection from peanut‐induced anaphylaxis in a murine model of peanut allergy.

show abstract

Section: Discussionmentioning

confidence: 97%

Immunotherapy using algal‐produced Ara h 1 core domain suppresses peanut allergy in mice

Gregory

Shepley-McTaggart

Umpierrez

et al. 2016

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Chemical modification of allergens to reduce IgE‐binding, but retaining their immunogenicity, has been suggested to improve safety of vaccines. This strategy was illustrated by acetylation of the major mugwort pollen allergen Art v 1 carried out by Perovic et al [169], and explored by Carnes et al [170], in depigmented allergoids of Betula alba . Relevant inhalant animal allergens, such as HDM ( Dermatophagoides pteronyssinus ) Der p 1 and Der p 2, have been also modified to better fulfil requirements for future safer specific IT.…”

Section: Allergensmentioning

confidence: 99%

“…Three major topics have been covered in this section during the last year: (1) the identification, characterization and determination of biological activity of allergens from plant foods, pollens, mites and ant sting [36,[159][160][161][162][163][164][165][166]; (2) the use of molecular markers and the biochemical modification of pollen and HDM allergens to enhance diagnosis and IT [167][168][169][170][171][172], and (3) the effect of proteolytic digestion and heat treatment on the allergenic properties of plant foods and cow's milk proteins [173][174][175][176].…”

Section: Allergensmentioning

confidence: 99%

Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy

Chu¹,

Lloyd²,

Karmaus³

et al. 2010

Clin Experimental Allergy

View full text Add to dashboard Cite

In 2009 the journal published in the region of 200 papers including reviews, editorials, opinion pieces and original papers that ran the full gamut of allergic disease. It is instructive to take stock of this output to determine patterns of interest and where the cutting edge lies. We have surveyed the field of allergic disease as seen through the pages of Clinical and Experimental Allergy (CEA) highlighting trends, emphasizing notable observations and placing discoveries in the context of other key papers published during the year. The review is divided into similar sections as the journal. In the field of Asthma and Rhinitis CEA has contributed significantly to the debate about asthma phenotypes and expressed opinions about the cause of intrinsic asthma. It has also added its halfpennyworth to the hunt for meaningful biomarkers. In Mechanisms the considerable interest in T cell subsets including Th17 and T regulatory cells continues apace and the discipline of Epidemiology continues to invoke a steady stream of papers on risk factors for asthma with investigators still trying to explain the post-second world war epidemic of allergic disease. Experimental Models continue to make important contributions to our understanding of pathogenesis of allergic disease and in the Clinical Allergy section various angles on immunotherapy are explored. New allergens continue to be described in the allergens section to make those allergen chips even more complicated. A rich and vibrant year helpfully summarized by some of our associate editors.

show abstract

“…The final concentrations of the compounds in cell suspension ranged between 0,001-100 μM (L) 0,0001-10 μM (1), 0,5-500 μM for (4). Cell survival was determined by MTT test [26][27][28].…”

Section: Preparation and Treatment Of Pbmcmentioning

confidence: 99%

Synthesis, characterization and antitumor activity of Cu(II), Co(II), Zn(II) and Mn(II) complex compounds with aminothiazole acetate derivative

et al. 2010

View full text Add to dashboard Cite

This paper presents the synthesis of complex compounds of type [M(L1)2], where M(II)= Cu (1), Co (2), Zn (3), L1=2-aminothiazole-4-acetate and [Mn(L1)2(H2O)] (4) using ethyl 2-(2-aminothiazole-4-yl) acetate (L), and characterization by elemental analysis, magnetic susceptibilities, IR, 1H-NMR, UV-Vis spectroscopy and for [Mn(L1)2(H2O)] also by X-ray diffraction. In vitro cytotoxicity studies were performed on human cervix adenocarcinoma, HeLa cells. The antitumor selectivity was assessed using normal human peripheral blood mononuclear cells, PBMC as control.

show abstract

Allergenicity and immunogenicity of the major mugwort pollen allergen Art v 1 chemically modified by acetylation

Abstract: Art v 1 modified by acetylation had a significantly reduced allergenicity in vitro and in vivo, while its immunogenicity was retained. Modification of allergens by acetylation could be a new strategy for allergen-specific immunotherapy.

Cited by 9 publications

References 43 publications

Immunotherapy using algal‐produced Ara h 1 core domain suppresses peanut allergy in mice

Immunotherapy using algal‐produced Ara h 1 core domain suppresses peanut allergy in mice

Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy

Synthesis, characterization and antitumor activity of Cu(II), Co(II), Zn(II) and Mn(II) complex compounds with aminothiazole acetate derivative

Contact Info

Product

Resources

About